All authors, Memorial Sloan-Kettering Cancer Center; and Gary A. Ulaner, Craig H. Moskowitz, and Andrew D. Zelenetz, Weill Cornell Medical College, New York, NY.
J Clin Oncol. 2014 Jan 1;32(1):51-6. doi: 10.1200/JCO.2013.50.8044. Epub 2013 Nov 18.
Determine the clinical significance of [(18)F]fluorodeoxyglucose (FDG)-avid lesions in patients with lymphoma treated with stem-cell transplantation.
All patients who underwent stem-cell transplantation for lymphoma at Memorial Sloan-Kettering Cancer Center between January 2005 and December 2009 and had post-transplantation FDG positron emission tomography/computed tomography (PET/CT) examinations were included. PET/CT examinations were evaluated for FDG-avid lesions suggestive of disease. Clinical records, biopsy results, and subsequent imaging examinations were evaluated for malignancy.
Two hundred fifty-one patients were identified, 107 with allogeneic and 144 with autologous stem-cell transplantation. Of allogeneic stem-cell transplantation recipients, 50 had FDG-avid lesions suggestive of lymphoma, defined as FDG-avidity greater than liver background. However, only 29 of these 50 demonstrated lymphoma on biopsy, whereas biopsy attempts were benign in the other 21 patients. Sensitivity analysis determined that a 1.5-cm short axis nodal measurement distinguished patients with malignant from nonmalignant biopsies. In 21 of 22 patients with FDG-avid lymph nodes ≤ 1.5 cm, biopsy attempts were benign. In the absence of treatment, these nodes either resolved or were stable on repeat imaging. Disease-free survival of patients with FDG-avid ≤ 1.5 cm lymph nodes was comparable with patients without FDG-avid lesions. In comparison, autologous stem-cell transplantation patients rarely demonstrated FDG-avid lesions suggestive of disease without malignant pathology.
Twenty percent (21 of 107) of patients with an allogeneic stem-cell transplantation demonstrated FDG-avid lymph nodes up to 1.5 cm in short axis on PET/CT, which did not represent active lymphoma. After allogeneic stem-cell transplantation of patients with lymphoma, benign FDG-avid ≤ 1.5 cm lymph nodes can mimic malignancy.
确定接受干细胞移植治疗的淋巴瘤患者中[(18)F]氟代脱氧葡萄糖(FDG)摄取病灶的临床意义。
纳入 2005 年 1 月至 2009 年 12 月期间在纪念斯隆-凯特琳癌症中心接受干细胞移植治疗淋巴瘤的所有患者,并对其进行移植后 FDG 正电子发射断层扫描/计算机断层扫描(PET/CT)检查。对提示疾病的 FDG 摄取病灶进行 PET/CT 评估。评估临床记录、活检结果和随后的影像学检查以确定恶性肿瘤。
共确定 251 例患者,其中 107 例接受同种异体干细胞移植,144 例接受自体干细胞移植。在所有接受同种异体干细胞移植的患者中,有 50 例患者的 FDG 摄取病灶提示淋巴瘤,定义为 FDG 摄取高于肝脏背景。然而,在这 50 例患者中,仅有 29 例通过活检证实为淋巴瘤,而另外 21 例活检尝试为良性。敏感性分析确定 1.5 厘米短轴淋巴结测量值可区分恶性和非恶性活检。在 22 例 FDG 摄取的淋巴结≤1.5 厘米的患者中,活检尝试均为良性。在没有治疗的情况下,这些淋巴结在重复影像学检查时要么消退,要么保持稳定。FDG 摄取≤1.5 厘米的淋巴结的无病生存率与无 FDG 摄取病灶的患者相当。相比之下,自体干细胞移植患者很少出现无恶性病理学证据的 FDG 摄取病灶。
在接受同种异体干细胞移植的患者中,有 20%(21/107)患者的 PET/CT 显示 FDG 摄取的淋巴结短轴直径可达 1.5 厘米,这并不代表活动性淋巴瘤。在淋巴瘤患者接受异体干细胞移植后,良性的 FDG 摄取≤1.5 厘米的淋巴结可能会模拟恶性肿瘤。